Medicare Drug Price Negotiation: ‘Spillover Effect’ on Private Market Remains Fuzzy
The Biden administration on Aug. 29 released its long-awaited list of the first 10 drugs that will be subject to price negotiation in the Medicare program, representing the first major step toward implementing the most ambitious drug-pricing reform in the Inflation Reduction Act (IRA).
While the new price-negotiation program will apply only to Medicare — not employer-based or individual market plans — industry experts say it will almost certainly affect the commercial insurance market indirectly. But they tell AIS Health, a division of MMIT, that exactly what the impact will look like hasn’t fully come into focus.
© 2025 MMIT
Related Posts

September
1
Majority of Drugs Selected for Price Negotiation Are on ‘Preferred’ Tiers in Medicare
READ MORE
August
18
For Some Insurers, Inflation Reduction Act’s Anniversary Is Reason to Celebrate
READ MORE
August
18